General anesthetics

Ketamine Media Creates Strategic Partnership With Microdose Psychedelic Insights for the Ketamine Conference - a Molecular Masterclass

Retrieved on: 
Friday, August 7, 2020
Psychoactive drugs, Drugs, Neurochemistry, Amines, General anesthetics, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Ketamine, Microdosing

KNOXVILLE, Tenn., Aug. 7, 2020 /PRNewswire/ -- Ketamine Media , the first digital agency dedicated to raising awareness for the clinical use of ketamine, announced today the launch of a new strategic partnership with Microdose Psychedelic Insights for their upcoming Ketamine Conference - A Molecular Masterclass .

Key Points: 
  • KNOXVILLE, Tenn., Aug. 7, 2020 /PRNewswire/ -- Ketamine Media , the first digital agency dedicated to raising awareness for the clinical use of ketamine, announced today the launch of a new strategic partnership with Microdose Psychedelic Insights for their upcoming Ketamine Conference - A Molecular Masterclass .
  • Ketamine Media will be joining Microdose , as well as Bexson Biomedical , and the Conscious Fund at The Ketamine Conference on Aug. 21 and 22.
  • "We are excited to welcome Ketamine Media as our media sponsor for The Ketamine Conference," says Patrick Moher, Partner, Microdose Psychedelic Insights.
  • If you would like to learn more about The Ketamine Conference or Ketamine Media please contact us below for more information.

DGAP-News: PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE PROGRAM FOR REMIMAZOLAM IN BELGIUM

Retrieved on: 
Monday, August 3, 2020
Psychoactive drugs, Drugs, Neurochemistry, GABAA receptor positive allosteric modulators, Anesthesia, Sedatives, RTT, General anesthetics, Remimazolam, Ketamine, Medication, Sedation, remimazolam, PAION

Aachen (Germany), 03 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that the Federal Agency for Medicines and Health Products in Belgium (FAMHP) has granted approval for the compassionate use of remimazolam, an ultra-short-acting benzodiazepine sedative/anesthetic.

Key Points: 
  • Aachen (Germany), 03 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that the Federal Agency for Medicines and Health Products in Belgium (FAMHP) has granted approval for the compassionate use of remimazolam, an ultra-short-acting benzodiazepine sedative/anesthetic.
  • PAION will fulfill requests from hospitals as quickly and as much as possible and will deliver the material initially free of charge.
  • Within a compassionate use program, medicines can be made available to patients if sufficient indication of the efficacy and safety of the medicinal product exists.
  • In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation.

Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

Retrieved on: 
Monday, August 3, 2020
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, General anesthetics, Glutamate, Amines, Nicotinic antagonists, Esketamine, Ketamine, Glutamate receptor, N-Methyl-D-aspartic acid

The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated.

Key Points: 
  • The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated.
  • Click to Tweet : #BREAKINGNEWS: FDA approves a new indication for @JanssenUS medicine for depressive symptom improvement in adults with major depression and suicidal behavior.
  • Forpatients who need help getting started on SPRAVATO and staying on track, Janssen CarePath offers a comprehensive support program.
  • SPRAVATO (esketamine) CIII nasal spray is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor an ionotropic glutamate receptor.

Sedative that Received FDA Emergency Use Authorization Now Available from Fresenius Kabi for use in Mechanically Ventilated COVID-19 patients

Retrieved on: 
Monday, June 15, 2020
Infectious diseases, FDA, Pharmaceutical, Health, Drugs, RTT, GABAA receptor positive allosteric modulators, General anesthetics, Chemistry, Physical sciences, Fresenius, Societates Europaeae, Propofol, Emergency Use Authorization, Propoven 2%, Fresenius Kabi

Fresenius Kabi announced today that following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), Fresenius Kabi Propoven 2% (propofol 20 mg/mL) Emulsion 100 mL is now available in the U.S.

Key Points: 
  • Fresenius Kabi announced today that following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), Fresenius Kabi Propoven 2% (propofol 20 mg/mL) Emulsion 100 mL is now available in the U.S.
  • View the full release here: https://www.businesswire.com/news/home/20200615005199/en/
    Fresenius Kabi received FDA Emergency Use Authorization for Propoven 2% (propofol 20 mg/mL) for mechanically ventilated COVID-19 patients.
  • The availability in the U.S. of Fresenius Kabi Propoven 2% under Emergency Use Authorization provides clinicians with another sedation option for their COVID-19 patients, said Seema Kumbhat, M.D., senior vice president and regional medical director at Fresenius Kabi USA.
  • Consistent with the EUA, Fresenius Kabi USA will offer the following presentation of Fresenius Kabi Propoven 2% (propofol 20 mg/mL) Emulsion:

DGAP-News: PAION ANNOUNCES APPROVAL OF COMPASSIONATE USE FOR REMIMAZOLAM IN ITALIAN HOSPITAL

Retrieved on: 
Tuesday, June 2, 2020
GABAA receptor positive allosteric modulators, Medical specialties, Chemical compounds, Medicine, Anesthesia, RTT, General anesthetics, Benzodiazepines, Remimazolam, Midazolam, Propofol, Sedation, remimazolam, PAION

PAION was contacted by the San Raffaele Hospital as to whether remimazolam could be delivered since a shortage of propofol and midazolam due to the coronavirus pandemic occurred.

Key Points: 
  • PAION was contacted by the San Raffaele Hospital as to whether remimazolam could be delivered since a shortage of propofol and midazolam due to the coronavirus pandemic occurred.
  • PAION will fulfill the request from the hospital and will deliver the material free of charge.
  • Remimazolam has received marketing authorization in Japan, and marketing approval applications have been submitted inter alia in the U.S. and in Europe.
  • In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation.

Sommetrics and aerFree, LLC Contributing to Treatment of COVID-19

Retrieved on: 
Wednesday, May 13, 2020
Infectious diseases, Health, Medical Supplies, Medical devices, Medicine, Medical specialties, Health, RTT, GABAA receptor positive allosteric modulators, General anesthetics, Mechanical ventilation, Alkylphenols, Propofol, Food and Drug Administration, Sommetrics, Inc., aerFree, LLC

aerFree is a FDA cleared, single use product intended to maintain the patency of the upper airway during medical procedures utilizing non-propofol sedatives.

Key Points: 
  • aerFree is a FDA cleared, single use product intended to maintain the patency of the upper airway during medical procedures utilizing non-propofol sedatives.
  • Sommetrics also filed an Emergency Use Authorization request to use a modified aerSleep product to support patients with COVID-19 related respiratory impairment who are not candidates for mechanical ventilation.
  • Aer+ is the basis of Sommetrics Inc and aerFree LLC products and numerous issued and filed patents.
  • aerFree and aerSleep are registered trademarks of Sommetrics; aer+ is a trademark of Sommetrics.

Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP

Retrieved on: 
Tuesday, May 12, 2020
Physical sciences, Chemistry, Drugs, GABAA receptor positive allosteric modulators, RTT, General anesthetics, Alkylphenols, AstraZeneca, Propofol, Emulsion

For more information, please visit: www.hikma.com

Key Points: 
  • For more information, please visit: www.hikma.com
    Important Safety Information for Propofol Injectable Emulsion, USP
    Propofol injectable emulsion is contraindicated in patients with a known hypersensitivity to propofol or any of its components.
  • Propofol injectable emulsion is contraindicated in patients with allergies to eggs, egg products, soybeans or soy products.
  • Propofol injectable emulsion should not be coadministered through the same IV catheter with blood or plasma because compatibility has not been established.
  • Propofol injectable emulsion vial is never to be accessed more than once or used on more than one person.

Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP

Retrieved on: 
Tuesday, May 12, 2020
Physical sciences, Chemistry, Drugs, GABAA receptor positive allosteric modulators, RTT, General anesthetics, Alkylphenols, AstraZeneca, Propofol, Emulsion

For more information, please visit: www.hikma.com

Key Points: 
  • For more information, please visit: www.hikma.com
    Important Safety Information for Propofol Injectable Emulsion, USP
    Propofol injectable emulsion is contraindicated in patients with a known hypersensitivity to propofol or any of its components.
  • Propofol injectable emulsion is contraindicated in patients with allergies to eggs, egg products, soybeans or soy products.
  • Propofol injectable emulsion should not be coadministered through the same IV catheter with blood or plasma because compatibility has not been established.
  • Propofol injectable emulsion vial is never to be accessed more than once or used on more than one person.

Vizient Applauds FDA’s Temporary Policy Enabling Hospitals to Compound Essential Medications Required for Hospitalized Patients During COVID-19 Emergency

Retrieved on: 
Friday, April 17, 2020
Medical Supplies, Health, Infectious diseases, Hospitals, Practice Management, Pharmaceutical, Drugs, Psychoactive drugs, Neurochemistry, RTT, General anesthetics, Analgesics, Euphoriants, Sedatives, Fentanyl, Midazolam, Pharmacy, Ketamine, Medical Supplies, Health, Infectious diseases, Hospitals, Practice Management, Pharmaceutical, Drugs, Psychoactive drugs, Neurochemistry, RTT, General anesthetics, Analgesics, Euphoriants, Sedatives, Fentanyl, Midazolam, Pharmacy, Ketamine

The medications include forms of fentanyl, midazolam, cisatracurium and ketamine that have seen unprecedented levels of demand and declining fill rates as the number of coronavirus patients has increased.

Key Points: 
  • The medications include forms of fentanyl, midazolam, cisatracurium and ketamine that have seen unprecedented levels of demand and declining fill rates as the number of coronavirus patients has increased.
  • Vizient began sounding the alarm more than two weeks ago about sedatives as well as two other classes of medications, analgesics and paralytics that are required for ventilated patients.
  • At that time, the companys pharmacy experts offered recommendations to the FDA to help expand access for providers.
  • The Vizient pharmacy team is monitoring the drugs required for ventilator patients daily and the heightened demand is not waning, but staying steady.

Global Ketamine Market Research Report, 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 26, 2020
Pharmaceutical, Health, Other Health, Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Amines, Ketamine, RTT, Market research

The "Ketamine (CAS 6740-88-1) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ketamine (CAS 6740-88-1) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Ketamine.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Ketamine global market report key points: